Caribou Biosciences, Inc. announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer. Dr. Rizvi has more than two decades of experience in all stages of drug development, from clinical strategy and execution through regulatory submissions to support approval and commercialization of several cancer treatments, including two autologous CAR-T cell therapies ABECMA® and BREYANZI®. Dr. Rizvi most recently served as chief medical officer of Chimeric Therapeutics, where he led the strategy and execution of clinical development programs for the company's T cell and NK cell therapy platforms and helped build the pipeline.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | +0.70% | -27.76% | -62.30% |
06-04 | US Equities Markets Close Mixed Monday as US Manufacturing Contracts | MT |
06-04 | HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.30% | 194M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- CRBU Stock
- News Caribou Biosciences, Inc.
- Caribou Biosciences, Inc. Appoints Syed Rizvi as Chief Medical Officer